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Abstract
Organs-on-chips are three-dimensional, microfluidic cell culture systems that simulate the function of tissues and
organ subunits. Organ-on-chip systems are expected to contribute to drug candidate screening and the reduction
of animal tests in preclinical drug development and may increase efficiency of these processes. To maximize the
future impact of the technology on drug development, it is important to make informed decisions regarding the
attributes and features of organs-on-chips even though the technology is still in a stage of early development. It is
likely that different stakeholders in organ-on-chip development, such as engineers, biologists, regulatory scien-
tists, and pharmaceutical researchers, will have different perspectives on how to maximize the future impact of
the technology. Various aspects of organ-on-chip development, such as cost, materials, features, cell source,
read-out technology, types of data, and compatibility with existing technology, will likely be judged differently
by different stakeholders. Early health technology assessment (HTA) is needed in order to facilitate the essential
integration of such potentially conflicting views in the process of technology development. In this critical review
we discuss the potential impact of organs-on-chips on the drug development process, and we use a pilot study to
give examples of how different stakeholders have different perspectives on attributes of organ-on-chip technol-
ogy. As a future tool in early HTA of organs-on-chips, we suggest the use of multicriteria decision analysis
(MCDA), which is a formal method to deal with multiple and conflicting criteria in technology development.
We argue that it is essential to design and perform a comprehensive MCDA for organ-on-chip development,
and so the future impact of this technology in the pharmaceutical industry can be maximized.
Key words: drug development, early health technology assessment, multicriteria decision analysis, organs-on-
chips
Introduction
Drug development is an expensive and lengthy pro-cess. A study published in 2012 indicates that drug de-
velopment costs $1.2 billion per successfully developed
drug.1 Moreover, it takes, on average, 10–15 years of preclin-
ical and clinical testing before a new drug reaches the mar-
ket. Only 27% of drugs that enter the clinical trial phase of
the drug development process are approved for market.2
Main reasons for drugs to fail in clinical trials are lack of ef-
ficacy (43%) and toxicity (33%).3 A new promising technol-
ogy for early validation of drug efficacy and detection of
toxicity is organs-on-chips.4 In this review, we discuss
organ-on-chip technology and its potential impact on drug
development. We focus on the role of early health technol-
ogy assessment (HTA) in maximizing the impact of organs-
on-chips on the pharmaceutical industry. The review consists
of four sections. In the first section, we describe what organs-
on-chips are and how they can potentially be used in the drug
development process. In the second section, we will focus on
the importance of early HTA and especially the use of multi-
criteria decision analysis (MCDA) in the early stages of tech-
nology development. The third section then introduces the
results of a survey among stakeholders in organ-on-chip de-
velopment to inform a full MCDA model that can guide fur-
ther development of organ-on-a-chip technologies. This
section will show the differences in opinions of two partici-
pating stakeholder groups, therefore proving the importance
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of including different stakeholder groups in the early phase
of development and therefore in the MCDA model. In the
fourth section, we motivate our recommendation of carrying
out a full MCDA in order to maximize the future impact of
organs-on-chips on drug development.
Organs-on-Chips
Organs-on-chips are engineered devices that combine
cells, biomaterials, and microfabrication to simulate the ac-
tivity and function of tissues and organ subunits. They are
often in multichannel three-dimensional microfluidic for-
mats that mimic cell responses more accurately than regular
in vitro cell cultures in two dimensions.5 The devices inte-
grate microengineered three-dimensional tissue with micro-
fluidic network systems,6 allowing living cells to be
cultured in micrometer-sized chambers that are continuously
perfused, thereby modeling essential functions of living or-
gans or tissues at a small scale.7 The microenvironment of
the cell culture can be tailored to mimic an organ very real-
istically; for example, biophysical constraints such as me-
chanical strain associated with breathing in the lung can be
included, or perfusion with blood or blood substitutes at
rates equivalent to the true shear stress on blood vessel
walls (Fig. 1).4,8 Cells can be grown as monocultures using
just one cell type or as co-cultures of two or more cell
types in two dimensions on, for example, a permeable mem-
brane, or in three dimensions.7
Apart from the ‘‘standard’’ organ-on-chip systems, which
are generated to mimic healthy organs or parts of organs, dis-
ease models on chips are also being developed. These disease
models range from breast cancer models and polycystic kid-
ney disease to Parkinson’s disease.9 These organ-on-chip
disease models can provide insights into disease mechanisms
and responses of the diseased tissue to drugs as well as the
target organ tissue.9 Recent technology development has fo-
cused on connecting multiple organs-on-chips, making it
possible to observe specific systemic interactions in drug
toxicity and efficacy,7,10 and on combining organ-on-chip
systems with human pluripotent stem cells, creating organs-
on-chips with potential for personalized medicine.11–13
Organs-on-Chips in Drug Development
Because of their physiological relevance, organs-on-chips are
often considered as key future technology in several phases in
drug development. The basic research phase, which consists of
target identification and high-throughput screening, could possi-
bly be improved by a relatively simple organ-on-a-chip system,
whereasmore complicated systems could be suitable to improve
the preclinical development phase, where pharmacokinetics,
pharmacodynamics, and in vitro and in vivo toxicities are deter-
mined. Potential advantages mentioned in the literature include
suitability for human toxicity screening,4,14–24 identification of
biomarkers and diagnostics,7,25 possible (partial) replacement
of animal experiments,4,6,14–16,19,20,22,25–31 and a higher sensi-
tivity to external stimuli compared with the standard two-
dimensional systems.10,16,17,26,32,33
There is a clear need for more physiologically relevant
model systems in drug development. Current assays in
early phase and preclinical development are often two-
dimensional in vitro cell culture systems or living animals.
Two-dimensional cell culture models are limited in their
ability to mimic key physiological parameters such as tissue
geometry, flow, pressure, and complex cell–cell and cell–
niche interactions. Animal models do capture these features
but are sensitive to possible species differences in disease
characteristics or drug responses, which can lead to miscal-
culation of drug efficacy in patients or their risks. Drugs
may be nontoxic or efficacious in animals but not in hu-
mans.17 Furthermore, animal studies are expensive and
time-consuming, and there are ethics questions on the use
of animals in drug development.27
The paucity of predictive models for preclinical drug
screening is a major problem that contributes to the rising
costs of developing new drugs. Given their unique features,
organs-on-chips have the potential to have a real impact on
lowering cost and time-to-market of drugs.
Maximizing Impact of Organs-on-Chips in Drug
Development
Organ-on-chip technology is still in an early phase of de-
velopment, but the first proof-of-concept systems already
demonstrate how organs-on-chips could be effectively
implemented in the drug development process and comple-
ment current high-throughput screening methods for identi-
fying drug candidates and targets.28 Alternatively, at the
preclinical stage of drug development, organs-on-chips
could provide additional information on human relevance,
which may eventually lead to partial replacement of animal
testing.34
There are, however, challenges in organ-on-chip develop-
ment, particularly in the design choices. These design
choices could be the following: what are the costs, which ma-
terials should be used, is there a preferred cell source, and
what on-chip sensors and analytical measures are available
and should be used? A combination of these choices could
also be preferred; however, not all design choices can be
implemented, and therefore trade-offs have to be made.
Which choices have a higher weight according to stakehold-
ers? There are many ways of using organ-on-chip systems in
drug development, and therefore the dialog between devel-
opers (or researchers) and other stakeholders at an early
stage is important to decide the exact steps that should be
taken in the development. On the one hand, the developers
are important stakeholders with respect to their knowledge
of the possibilities and limitations of the technology. For ex-
ample, there are still several challenges to overcome before
multiple organs can be connected.35,36
On the other hand, future end-users should also be in-
cluded to give their view on how organ-on-chip technology
could have an impact on drug development. The exact pur-
pose of the model is an important factor that can be defined
by asking questions such as, ‘‘Do the users need a model for
general toxicity screening or for a specific target organ?’’ and
‘‘What are the most valuable read-outs for toxicity?’’ Fur-
thermore, the specific pharmacological information that the
model should yield is an important factor. Examples of ques-
tions related to this factor are as follows: ‘‘Do the users need
a system to model the effects of different drug dosages or the
properties of the drug at certain dosages?’’ ‘‘How long does
the model need to be viable?’’ and ‘‘How can a drug best be
delivered? Another factor that can be surveyed is how differ-
ent end-users think about concrete design choices, for
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FIG. 1. Microfluidic lung-on-a-chip: The chip consists of two channels, which represent the alveolar air compartment and
the alveolar capillary. Top right illustrates the standard setup of the chip. The upper channel represents the alveolar air com-
partment through which air can flow, whereas the lower channel represents the alveolar capillary through which a ‘‘blood-
like’’ substance can be pumped. The channels are separated by a porous membrane on which lung epithelium (air compart-
ment) and endothelium (capillary compartment) are seeded (see bottom left). The vacuum channels on each side of the air and
capillary channels can be used to stretch the porous membrane to which the cells are attached to mimic breathing motion of
the human lung (bottom right). Figure has been reproduced with permission from Huh et al.4
FIG. 2. Schematic over-
view of the multicriteria de-
cision analysis (MCDA)
process. MCDA starts with
defining the problem, after
which an appropriate MCDA
model can be chosen.39 The
evidence is collected, which
can be used to understand the
criteria and alternatives better
and to capture hard evidence
for the next step, where a
quantitative measurement of
the values is performed. A
choice can be made after
considering the results of the
analysis. It is worth noting
that it is always possible to
take a step back in the process
and repeat a step with evi-
dence gathered later in the
process. Adapted from Tho-
kala and Duenas42 and Hum-
mel et al.43 Examples with
regard to organs-on-chips are
provided for the first step, to
give an indication.
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example, by asking questions such as, ‘‘Does this model
need to be organ or tissue specific?’’ ‘‘Would end-users pre-
fer a more specific disease model?’’ ‘‘How many target cell
types should be included?’’ ‘‘Is it easier to use than the cur-
rent golden standard models?’’ and ‘‘Is it important to in-
clude multiple connected organs on one chip?’’ Finally, an
essential consideration is how to factor in the cost and eco-
nomic impact of organs-on-chips in drug development, for
example, by asking: ‘‘What would be the acceptable cost
per data point?’’ Different users could have different opin-
ions. The users could be academic researchers in a university
(biomedical research) or pharmaceutical companies. These
two groups can differ significantly in opinions because of
the different purposes of the systems. One difference in pur-
pose can be where in the drug development process the sys-
tem will be used. Pharmaceutical companies can be inclined
to want a simple model that works faster than the now used
well-plate, whereas stakeholders from a university could be
more interested in understanding the mechanism behind an
organ system and being able to publish.
Another important stakeholder group is the regulators.
Even if a decision can be made on how the technology devel-
opment should proceed, regulators have to approve the use of
data from organ-on-chip systems as a substitute for current
drug safety screening methods. Thorough validation in com-
parison to existing regulatory requirements is essential.
It is complex to consider all aspects of stakeholder prefer-
ences and possible applications of technology development
in a comprehensive manner, and therefore it is imperative
to have a formal method of deciding what should be priori-
tized in the development and what will be the possible ben-
efits of this prioritization.
Early Health Technology Assessment
Early HTA, including early health economic modeling, is
increasingly promoted as an approach to determine added
value of potential new technologies early in the development
pipeline. Such assessments would be useful to 1) decide
about further development of the technology, 2) to define
minimum performance thresholds for the new technology
compared with currently available technologies, and 3) to
support pricing and reimbursement in early stages of devel-
opment.37–39
Early HTA can help developers in their decisions about
the design of a device while it is still under development.
This is possible even at the stage where there is still no
proof-of-concept prototype to convince regulatory decision
makers or end-users.40 A systematic assessment can still be
made in a phase in which the developers can still make mean-
ingful changes to the design. Therefore, by applying early
HTA, developers can improve the chances of developing a
successful product that will find acceptance by end-users
and regulatory agencies.41
There are various methods that can be used in early HTA:
these include assessment of potential impact by conducting
surveys, analysis of costs and benefits by economic model-
ing, and scenario-driven computer simulations of clinical tri-
als. Which method is most suitable for early HTA depends
on the stage of technology development and the intended
party for decision making.40 For the translational stage of de-
velopment of current organ-on-chip technology—a stage
that revolves around making crucial decisions in terms of
design—the most dominant perspective is to identify the
most promising organ-on-chip application area, and to figure
out its societal impact. This would help to justify allocating
resources to its development and hopefully increase the like-
lihood of delivering societal impact.
In such analysis, MCDA may be particularly useful as an
aid for decision making about the design of technological in-
novations by comparing several organ-on-chip alternatives
on a set of relevant development criteria. The criteria can
be conflicting and may require a trade-off with regard to
their importance. The importance of criteria, that is, their
weights, can be elicited from various stakeholders, such as
R&D or academic representatives. An MCDA study usually
comprises five sections (Fig. 2). The first step is structuring
the decision problem. The decision problem is structured
by defining the decision goal, identifying the decision criteria
and alternatives. Figure 2 shows an example of this step
when organs-on-chips are involved, describing what the dif-
ferent components of problem structuring could entail in an
MCDA. After this step is performed, the researcher can se-
lect the appropriate MCDA model to support making the de-
cision (with regard to available resources obtained in the first
step). One example could be an outranking model where
different alternatives (organs-on-chips, animal models) are
ranked in order of decreasing preference. Other models go
one step further and prioritize the preferences for the alterna-
tives. The next step is estimating the performance of the al-
ternatives; for instance, how would the organ-on-a-chip
perform in toxicity testing? This performance evidence can
be obtained either by a systematic literature review or by
interacting with stakeholders, and is usually converted into
a partial value function to allow comparison across criteria.
The fourth step is the elicitation of criteria weights for the
organ-on-chip alternatives such as that for cost of develop-
ment and for toxicity testing in phase I trials. Different crite-
ria (costs, toxicity) are used to aggregate a preference for one
alternative over the other with regard to the set goal. By
(quantitative) weighting the importance of the criteria, the
differences in importance of the criteria to reach the goal
can be integrated in the model. The questions here could
be: What is more important for reaching the goal? Is it low
development costs or better toxicity screening? If the goal
would need a better toxicity screening, this criterion would
have a high weight and organ-on-a-chip would score higher.
The final step is to aggregate the value by multiplying criteria
weights and performance values for the alternatives.42,43 We
will not go further into the details of how to carry out an
MCDA in this review, and the reader is recommended to
read the following contributions for framework and setup
of the MCDA process.40,42–44
When performing early HTA, it is also important to in-
clude all relevant stakeholder groups so that they can pro-
vide input on key aspects of the MCDA such as
identification of the criteria and the alternatives to priori-
tize. If not all stakeholders are included or if there is a fail-
ure to communicate between all stakeholders, then this
could lead to errors in the description of the problem or
the deliberation.45 The weighting of criteria in a MCDA
model can differ significantly between different stakeholder
groups, which could lead to a different end result for the
best alternative. Including all stakeholders can therefore
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help in understanding the needs and position of developers
as well as users and can prevent conflicts later on in the de-
velopment process.46
When including all stakeholders early on in the HTA pro-
cess, differences between groups can become clear and
therefore the technology developers can anticipate on the
needs of the end-users.
Stakeholders and Organ-on-Chip Technology
Development
As an illustration of the importance of involving stake-
holders in early HTA of organs-on-chips, we have carried
out a pilot study in which mostly university employees (in-
volved in the development of organ-on-chip systems or
drug development) and pharmaceutical company employees
were included. This study was not a full MCDA process, but
merely shows the expectations of the two stakeholder groups.
This survey can therefore not be used to elicit weight and to
prioritize alternatives, but is, however, an important part at
the beginning of an MCDA process to capture evidence to
structure the problem by defining key issues and criteria.
These key issues and criteria can be used for a full MCDA
study.
The stakeholders were asked to give their opinion on var-
ious aspects of organ-on-chip technology in the context of
drug development. The survey was designed to observe
whether there were significant differences of opinions be-
tween different stakeholder groups, proving the importance
of including all stakeholders in the development process.
For details of the survey (including results) and study plan,
see online data supplement.47
The survey was sent out to approximately 150 people
using an e-mail invitation. It was filled out by 50 stakehold-
ers. Of these 50 stakeholders, 18 people (36%) were working
in a pharmaceutical company and 22 (44%) were working for
a university. Other respondents indicated to be working for a
commercial company (n = 5 or 10%), nonprofit organization
(n = 4 or 8%), or other (n = 1 or 2%). The two main groups
were the pharmaceutical stakeholders (participant’s work
ranging from general scientists to scientific directors) and
the university stakeholders (participants ranging from gen-
eral researchers to professors in the field of either drug devel-
opment and/or organs-on-chip development). No distinction
was made with regard to the individual’s job description be-
cause of the lack of statistical certainty for such small groups.
One of the main questions in the survey was where organs-
on-chips could be beneficial in drug development. Figure 3A
shows an overview of opinions of all stakeholders. There
were no significant differences between the opinions of the
stakeholders, and therefore all stakeholder groups were in-
corporated in one sample. The three main phases of drug de-
velopment are basic research, preclinical research, and
clinical trials. The stakeholders were asked which phase of
drug development could be improved by implementation of
organ-on-chip systems, and 90% of the stakeholders see im-
provement possibilities in the basic research phase, 88%
think that the preclinical development phase can be im-
proved, and 22% are of opinion that the clinical trial phase
can be improved. In the squares (which contain subcatego-
ries of the main development phases) it can be observed
that 70% of all stakeholders see possibilities for improve-
ment in (drug and disease) target identification in basic re-
search. More possibilities were predicted in the preclinical
development stage: 78% of all stakeholders see organs-on-
chips as a means of reducing animal use in drug development
and 74% expect an improvement in toxicity screening. The
opinions of different stakeholder groups were similar in
this example.
Stakeholders were also asked which organ model should be
developed with the highest priority as an organ-on-a-chip. The
three highest scoring organs were the liver, heart, and kidney.
However, stakeholders with a pharmaceutical background
rated the development of the lung asmore important than the de-
velopment of the heart, whereas university stakeholders scored
the heart as most important to develop first (see Fig. 3B).
There was no significant difference between the groups.
When the stakeholders were asked for their opinion on
specific advantages and disadvantages of using organs-on-
chips in drug development, a significant difference was ob-
served between stakeholders. They were asked to rank the
advantage from 1 (none) to 5 (very important). The first sta-
tistically significant difference was the overall average score
between university stakeholders and stakeholders working in
a pharmaceutical company, where the average score of ad-
vantages and average inverse score of the disadvantages
were used. The opinion of university stakeholders was
more positive (3.5) compared with the more neutral (3.1)
ranking of pharmaceutical stakeholders (paired, two-tailed
t-test; p = 0.000129).
Further statistical analysis showed a significant difference
between those working in pharmaceutical companies versus
those working in universities on the advantage for ‘‘replace-
ment/reducing human trials.’’ Figure 3C shows the distribu-
tion of ranking of both groups. The university stakeholders
see a higher potential for the replacement or reduction of
human trials.
Other advantages with significant differences in ranking
between pharmaceutical company stakeholders and univer-
sity stakeholders were ‘‘shorten the length of the drug devel-
opment’’ and ‘‘personalized medicine can be developed
easier.’’ Both were ranked higher by university stakeholders.
The first two advantages are based on conjecture and can
most likely be proven when organs-on-chips are accepted
into the drug development process and fully developed.
University stakeholders ranked the advantage ‘‘personal-
ized medicine’’ significantly higher than stakeholders
working at a pharmaceutical company. A reason could be
that pharmaceutical companies do not see enough profits
from personalized medicines, and therefore the pharma-
ceutical company stakeholders are not as familiar with
the concept and underlying human stem cell technology
as university stakeholders are.
There were also disadvantages of organ-on-chip technology
that were rated significantly different by university versus phar-
maceutical stakeholders. Stakeholders from pharmaceutical
companies considered the disadvantages as ‘‘difficult to obtain
human organ-specific cells with both proliferative capacity and
full differentiation capability’’ and ‘‘more expensive than well
plates’’ greater than university stakeholders.
These examples clearly demonstrate the need to include
all stakeholders in the decision-making process. The stake-
holder groups differed significantly when asked to attribute
importance to various aspects of the organ-on-chip
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FIG. 3. The importance of
involving stakeholders in the
early health technology as-
sessment process. (A) No
differences between stake-
holder groups were observed
when asked about the possi-
bilities of improving the drug
development process. The
basic research and preclinical
phase and subsections
(squares) were mostly se-
lected by both stakeholder
groups. (B) Also when asked
which organs an organ-on-
chip model should be devel-
oped first, both stakeholder
groups showed broad agree-
ment. (C) The responses of
the two stakeholder groups
showed significant differ-
ences when asked to score the
importance of the advantage,
‘‘Replacement or reduction of
human trials,’’ and the disad-
vantage, ‘‘Difficult to obtain
human organ specific cells
with both proliferative capac-
ity and full differentiation ca-
pability,’’ of organ-on-chip
technology. The differences
were evaluated with a Mann–
Whitney U-test; p= 0.015 for
the top graph, p=0.025 for the
bottom graph.
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technology. This information should be taken into account in
further development of organs-on-chips and form part of the
dialog between academics and industry.
Conclusions and Outlook
Organ-on-chip technology is broadly considered prom-
ising for drug development. The possibilities for imple-
mentation range from improvement of toxicity screening
to high-throughput drug and compound screening as well
as the potential to partially replace animal testing.
It is very clear that it is important to use a well-
established decision tool to determine which are the next
best steps in designing technology such as organs-on-
chips. Using MCDA in early HTA can be a helpful tool
in the decision-making process because it can be used to in-
tegrate the opinions of all stakeholders. Crucial design
choices can be made in organ-on-a-chip model development
based on the needs and wishes of the expected end-users. It
is important to know that an MCDA process will not give
the users a perfect answer to their question. It does help
in understanding the priorities and limitations of all groups
involved in technology development. It should be an evolv-
ing process; when a development step is taken, the re-
searcher could take a step back in the MCDA process and
determine whether the needs, priorities, and limitations
are similar to the information gathered previously. Making
the MCDA is not a linear process, but a cycle, in which
the development process is continually followed up with
an evaluation.
The examples in this review are the results of a pilot study
and show why involving different stakeholders in early HTA
could be helpful in the development of new techniques such
as organs-on-chips. The differences in opinion show that it is
essential to have high level of communication between de-
velopers and end-users from the very start of the develop-
ment of a new technology.
The examples that we presented were part of a first step
in gathering evidence. On the basis of the initial findings,
we propose the use of a full MCDA process to guide the
next steps in the development of organs-on-chips. After
the criteria and key issues are established, a survey can
be created to determine weights and calculate the preferred
next steps in the development. This MCDA process should
include all stakeholders to find general consensus on the
most important features and components to be prioritized
as well as the economic effect of the different design
choices.
In conclusion, we argue that it is imperative to use expert
input from health scientists and the formal methods of an
MCDA to direct the development of organs-on-chips toward
maximal impact in terms of partially replacing animals test-
ing and improving the efficiency of the drug development
process.
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